Acrobat Coronary Stent System Effectiveness European Study (ACES)

This study has been terminated.
(Difficulty to identify eligible patients: 8 centers contributed 54 patients in 6 months.)
Sponsor:
Information provided by (Responsible Party):
Svelte Medical Systems Europe
ClinicalTrials.gov Identifier:
NCT01761591
First received: December 12, 2012
Last updated: August 25, 2014
Last verified: August 2014
  Purpose

The purpose of this randomized controlled trial (RCT) is to demonstrate the clinical benefit and impact on resource utilization of percutaneous coronary interventions (PCI) with the Svelte Acrobat Stent System compared to any other CE marked bare metal stent (BMS) implantable via direct stenting or after lesion pre-dilation, in patients with coronary lesions that are eligible for direct stenting and who are recruited and treated so as to reflect real-life routine practice.


Condition Intervention
Coronary Artery Disease
Device: PCI with Svelte Acrobat
Device: PCI with other BMS

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Acrobat Coronary Stent System Effectiveness European Study (European Multicenter Effectiveness Randomized Study of Svelte Medical Systems Acrobat Stent on a Wire Compared to Other BMS PCI in de Novo Coronary Lesions) ACES Trial

Resource links provided by NLM:


Further study details as provided by Svelte Medical Systems Europe:

Primary Outcome Measures:
  • Proportion of patients free of Major Adverse Cardiac Event ("MACE-free patients") [ Time Frame: From the date and time of randomization until 6 months after the index procedure ] [ Designated as safety issue: No ]
    Major Adverse Cardiac Event ("MACE") is defined here as device-oriented composite endpoint that includes, in hierarchical order: Cardiac death (All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established), Myocardial Infarction ("MI"), Target Lesion Revascularization ("TLR").


Secondary Outcome Measures:
  • administered dye [ Time Frame: intra-procedural ] [ Designated as safety issue: No ]
    Volume (ml) of administered dye i.e. injected radiological contrast medium.

  • procedure duration [ Time Frame: intra-procedural ] [ Designated as safety issue: No ]
    Procedure duration (minutes) from arterial access to closure.

  • radiation exposure [ Time Frame: intra-procedural ] [ Designated as safety issue: No ]
    Radiation exposure (gY/cm²) & total fluoroscopy time (min)

  • acute success [ Time Frame: procedure to discharge ] [ Designated as safety issue: No ]

    Acute success is measured at procedure end according to 4 criteria:

    1. Lesion success: Residual stenosis of the target lesion < 30% of the RVD using any percutaneous method.
    2. Direct stenting success: Lesion success without unplanned pre-dilation performed (planned pre-dilation is an exclusion criterion) from the trial.
    3. Device Success: Direct stenting success without post-dilatation or with post-dilatation using the Stent Delivery System (SDS).
    4. Procedure success: Lesion success & no in-hospital MACE

  • heparin administration [ Time Frame: intra-procedural ] [ Designated as safety issue: No ]
    Amount of heparin administered during the procedure

  • adverse events [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]

    Adverse events occurrence:

    1. Death
    2. MI
    3. Repeat coronary revascularization
    4. Bleeding or vascular complications at discharge
    5. Stent thrombosis up to 6 months
    6. Other serious adverse events


Other Outcome Measures:
  • resource utilization [ Time Frame: 6 months ] [ Designated as safety issue: No ]

    Resource utilization (R.U.) endpoints:

    Overall procedural and follow-up R.U. including:

    • Man-time
    • Facility usage
    • Amount of medical devices and drugs used:

      1. during index procedure
      2. after index procedure until discharge
      3. between discharge and 6-month follow-up


Estimated Enrollment: 300
Study Start Date: December 2012
Study Completion Date: January 2014
Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Acrobat
Device: PCI with Svelte Acrobat
Device: PCI with Svelte Acrobat
Percutaneous coronary intervention with Svelte Acrobat Coronary Stent System
Active Comparator: Control BMS
Device: PCI with other BMS
Device: PCI with other BMS
Percutaneous coronary intervention with any other routine use CE marked bare metal stent (BMS) implantable either via direct stenting or after lesion pre-dilation

Detailed Description:

The main objectives of this study are to test the following hypotheses:

  1. The evaluated stent is clinically non-inferior to control BMS in terms of freedom of MACE
  2. The evaluated stent is clinically beneficial compared to control BMS by reducing exposure to radiations, amount of contrast medium administered, procedure time, as well as amount of administered heparin,
  3. The evaluated stent does not result in more frequent adverse events than control BMS,
  4. The evaluated stent improves direct stenting success while not decreasing procedural success compared to control BMS.
  5. Resource utilization (R.U.):

    1. Hospital-perspective resource utilization during the index admission and index procedure is not greater with evaluated the stent and potentially lower than with control BMS
    2. Resource utilization over a 6-month time-horizon, in relation to routine follow-up and MACE, is not greater with the evaluated stent than with control BMS.
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Eligible for PCI and demonstrating native vessel or vein/arterial graft disease
  • symptomatic CAD: either stable angina pectoris (CCS 1, 2, 3 pr 4) or unstable (Braunwald Class 1-3, B-C) or positive functional ischemia study
  • Male and post-menopausal female
  • Patient provides written informed consent prior to procedure
  • Patient willing to comply with protocol
  • Acceptable candidate for CABG
  • Patient indicated for stenting of one or more de novo stenotic lesions in native coronary arteries or bypass grafts with or without direct stenting
  • All target lesions for stenting in single or multi-vessel disease meet all inclusion criteria
  • None of the lesions requires stenting with Drug eluting stents
  • At least one lesion is visually estimated to be candidate for direct stenting
  • All target lesions for stenting have a visually estimatd RVD >= 2.5 mm and <= 3.5 mm
  • All target lesions for stenting are visually estimated to have LL =< 20 mm (to cover the lesion with 1 stent)
  • All target lesions for stenting visually estimated to have a stenosis > 50% and < 99%
  • All target lesions for stenting are ACS lesions TIMI flow >= 1

Exclusion Criteria:

  • Currently enrolled in another clinical trial that has not completed the primary endpoint or that clinically interferes with the current study endpoints
  • A previous coronary procedure within 30 days
  • Any of the target lesion(s) requires treatment with a device other than PTCA prior to stent placement (such as, but not limited to, directional coronary atherectomy, excimer laser, rotational atherectomy, etc.)
  • Previous BMS deployment anywhere in the target vessel within the past 6 months
  • Any DES deployment anywhere in the target vessel within the past 9 months
  • Any previous stent placement within 10 mm (proximal or distal) of the target lesion
  • Patient has diabetes mellitus
  • Co-morbid condition(s) that could limit the patient's participation or impact the trial
  • Documented LVEF < 30% at the most recent evaluation
  • Evidence of AMI within 72 hours of the intended trial procedure and/or with TIMI flow 0
  • History of CVA or TIA in the last 6 months
  • Leukopenia (<3.5 x 10^9/L)
  • Neutropenia (<1000/mm3) <= 3 days prior to enrollment
  • Thrombocytopenia (<10^5/mm3) pre-procedure
  • Active peptic ulcer or active GI bleeding
  • History of bleeding diathesis or coagulopathy or inability to accept blood transfusions
  • Known hypersensitivity or contraindication to aspirin, heparin or bivalirudin, clopidogrel or ticlopidine, cobalt, nickel, L-605 Cobalt chromium alloy or sensitivity to contrast media, which cannot be adequately pre-medicated
  • Serum creatinine level > 2.5 mg per dl within 7 days prior to index procedure
  • In-stent restenosis
  • Patient not able to give consent or read or write or protected by law or under guardianship or deprived of civil rights
  • Woman of childbearing age
  • Patient not covered by health or social insurance
  • Unprotected left main CAD with obstruction > 50% , not protected by at least one non-obstructed bypass graft to the LAD or left circumflex (LCX) artery or their branches
  • Target vessel exhibiting multiple lesions > 40% diameter stenosis outside of a range of 5 mm proximal and distal to the target lesion(s) to be stented based on visual estimate or on-line QCA
  • Any target lesion for stenting exhibits an intraluminal thrombus (occupying > 50% of the true lumen diameter) at any time
  • Any target lesion for stenting is excessively tortuous (two bends > 90° to reach the target lesion)
  • Lesion location that is aorto-ostial or within 5 mm of the origin of the LAD or LCX
  • Any target lesion for stenting is has side branches > 2.0 mm in diameter in which bifurcation stenting is planned
  • Any target lesion >20 mm
  • Any target lesion totally occluded (CTO)
  • Any target lesion has TIMI flow = 0
  • Any target lesion with ISR
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01761591

Locations
Belgium
OLV Ziekenhuis
Aalst, Belgium, B-9300
ZNA Middelheim - Hartcentrum
Antwerpen, Belgium, B-2020
ZOL Sint Jan
Genk, Belgium, B-3600
CHU Liège - Sart Tilman
Liège, Belgium, B-4000
France
CHU Nord Grenoble - A. Michalon
La Tronche, France, 38700
AP-HP La Pitié Salpétrière
Paris, France, 75651
AP-HP Hôpital Européen Georges Pompidou
Paris, France, 75015
CHU Bordeaux Sud - Hôpital Cardiologique Haut Lévêque
Pessac, France, 33604
Clinique St Hilaire
Rouen, France, 76000
Clinique Pasteur
Toulouse, France, 31300
CHU Rangueil
Toulouse, France, 31059
Spain
Hospital Universitari Vall d'Hebrón
Barcelona, Spain, 08035
Sponsors and Collaborators
Svelte Medical Systems Europe
Investigators
Principal Investigator: Jean Fajadet, MD Clinique Pasteur, 45 avenue Lombez, Toulouse 31300, France, Tel. 33 (0)5 62 21 16 99 - secretariat@interv-cardio-toul.com
Study Director: Andrew Schut Svelte Medical Systems, Inc., 675 Central Avenue, New Providence, NJ 07974, USA, Tel. 1.908.264.2181 - aschut@sveltemedical.com
  More Information

Additional Information:
Publications:
Responsible Party: Svelte Medical Systems Europe
ClinicalTrials.gov Identifier: NCT01761591     History of Changes
Other Study ID Numbers: Svelte_13-002, ID RCB: 2012-A00670-43
Study First Received: December 12, 2012
Last Updated: August 25, 2014
Health Authority: France: Institutional Ethical Committee
Belgium: Ethics Committee
Spain: Comité Ético de Investigación Clínica

Keywords provided by Svelte Medical Systems Europe:
CAD
PCI
BMS
Svelte
Acrobat
direct stenting
RCT

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases

ClinicalTrials.gov processed this record on August 28, 2014